thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-27. Numbers and descriptions here follow the published literature rather than marketing material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
The Terek Cossack Host was created in 1577 by free Cossacks resettling from the Volga to the Terek River. Local Terek Cossacks joined this host later. In 1792, the host was included in the Caucasus Line Cossack Host, from which it separated again in 1860, with Vladikavkaz as its capital. In 1916, the population of the host was 255,000, within an area of 1.9 million desyatinas.
== Selected articles == Ionescu‐Zanetti, C., Mechler, A., Carter, S. A., & Lal, R. (2004). Semiconductive polymer blends: Correlating structure with transport properties at the nanoscale. Advanced Materials, 16(5), 385–389. Thimm, J., Mechler, A., Lin, H., Rhee, S., & Lal, R. (2005). Calcium-dependent open/closed conformations and interfacial energy maps of reconstituted hemichannels. Journal of Biological Chemistry, 280(11), 10646–10654. Mechler, A., Praporski, S., Atmuri, K., Boland, M., Separovic, F., & Martin, L. L. (2007). Specific and selective peptide-membrane interactions revealed using quartz crystal microbalance. Biophysical Journal, 93(11), 3907–3916. Del Borgo, M. P., Mechler, A. I., Traore, D., Forsyth, C., Wilce, J. A., Wilce, M. C., ... & Perlmutter, P. (2013). Supramolecular self-assembly of N-acetyl-capped β-peptides leads to nano-to macroscale fiber formation. Angewandte Chemie International Edition, 52(32). Hasan, I. Y., & Mechler, A. (2017). Nanoviscosity measurements revealing domain formation in biomimetic membranes. Analytical chemistry, 89(3), 1855–1862. West, N. G., Bamford, S. E., Pigram, P. J., Pan, J., Qi, D. C., & Mechler, A. (2023). Controllable hierarchical self-assembly: systematic study forming metallosupramolecular frameworks on the basis of helical beta-oligoamides. Materials Horizons, 10(12), 5584–5596.
The Reconstruction (Greek: Αναπαράσταση, romanized: Anaparastasi) is a 1970 Greek dramatic black and white independent art film directed by Theo Angelopoulos. It is the director's first feature film. While based on true events, it transcends them to recall the ancient myths of the Atrides and Clytemnestra. In 1986, the Greek Film Critics Association named it the third-best Greek film in history.
Sources: en.wikipedia.org
=== Protein-based materials and sustainability === A major strand of Mezzenga's work concerns the development of protein-derived and food-based materials as sustainable platforms for advanced technologies. His group has pioneered the use of amyloid fibrils as building blocks for functional nanocomposites, including biodegradable materials with sensing and shape-memory properties. In 2016, Mezzenga and collaborators reported amyloid–carbon hybrid membranes for universal water purification. The technology exploits supramolecular metal–ligand interactions between heavy-metal ions and protein amyloid fibrils, allowing simultaneous removal of a wide range of contaminants with high binding affinities. The membranes exhibit unusually high permeability, enabling operation with minimal energy input. This research led to patented technologies and the creation of an ETH Zurich spin-off company, BluAct Technologies, which has tested and deployed the approach in multiple countries. Mezzenga has also contributed to the development of conceptual frameworks for evaluating the sustainability of water purification technologies at large, emphasizing energy efficiency and material performance.
In response to shifts in federal policy in the transition between the Biden and Trump administrations, Pritzker signed a number of bills codifying federal labor protections into state law: the Illinois Workers' Rights and Safety Act, which preserves regulations defined by the Occupational Safety and Health Act of 1970, the Fair Labor Standards Act of 1938, and the Federal Coal Mine Health and Safety Act of 1969, regardless of any changes at the federal level; an amendment to the Prevailing Wage Act that ensures that workers for federally funded construction projects administered by the state or local governments are paid the Illinois prevailing wage whenever it is higher than the federal rate; and a bill eliminating references to the Equal Pay Act of 1963 that would have tied some provisions to federal programs, so that federal changes will not undermine the state's requirement that employers with 100 or more employees report on wages by employees' gender and race or ethnicity.
Fort Bragg Homepage Archived 1 November 2020 at the Wayback Machine Historical Account of the 82nd Airborne Division Archived 9 June 2017 at the Wayback Machine All American: The Story of the 82nd Airborne Division – World War II unit history booklet, 1945 82nd Airborne Combat Footage DVD World War II Normandy June 1944 82nd AB Combat Footage DVD World War II including Operation Market Garden September 1944 The 82nd Airborne Division THE 82ND AIRBORNE DIVISION The 82nd Airborne during World War II 82nd Airborne Division, NYC Victory Parade, 12 Jan 1946 The short film Big Picture: Arctic Night is available for free viewing and download at the Internet Archive. The short film Big Picture: All American is available for free viewing and download at the Internet Archive. The short film Big Picture: This is Our Strength is available for free viewing and download at the Internet Archive. The short film STAFF FILM REPORT 66-17A (1966) is available for free viewing and download at the Internet Archive. The short film STAFF FILM REPORT 66-18A (1966) is available for free viewing and download at the Internet Archive. The short film STAFF FILM REPORT 66-19A (1966) is available for free viewing and download at the Internet Archive. The short film STAFF FILM REPORT 66-20A (1966) is available for free viewing and download at the Internet Archive. The short film STAFF FILM REPORT 66-25A (1966) is available for free viewing and download at the Internet Archive. The short film STAFF FILM REPORT 66-27A (1966) is available for free viewing and download at the Internet Archive.
Sources: en.wikipedia.org
Its main constituents are (1) reaction scheme, (2) target of project & deliverables (product, quantity, required dates, specifications), (3) list of analytical methods, (4) process development opportunities (stepwise assessment), (5) list of required reports, (6) Safety, Health and Environment (SHE) issues, (7) materials to be supplied by customer and (8) packaging & shipping information. The technical part of a project usually determines its duration. Depending on the quality of the information contained in the "technology package" received from the customer and the complexity of the project as such, particularly the number of steps that have to be performed, it can be anywhere from 12 to 24 months. Depending on the amount of research involved, the total budget easily amounts to several million US dollars.
== Description == Typical Catostylus with chunky appendages and tentacle to go with each. This jellyfish has a sting that causes light pain and a skin rash, but generally poses no serious threat. It is up to 65 cm (26 in) in bell diameter, but a more typical size is 25 cm (10 in) in diameter and 2.5 kg (5.5 lb) in weight. Its colour is variable and can be blue-white, cream, brown, or off-white. The exumbrellar grooves are reddish or purplish brown. C. tagi has gonads along the edge of its stomach in an X shape. It has the octant formation typical of Catostylus jellies, the height of the octants are also variable.
=== Cancer progression, tumor characterization === The mammographic density is correlated with the collagen density, thus SHG can be used for identifying breast cancer. SHG is usually coupled to other nonlinear techniques such as Coherent anti-Stokes Raman Scattering or Two-photon excitation microscopy, as part of a routine called multiphoton microscopy (or tomography) that provides a non-invasive and rapid in vivo histology of biopsies that may be cancerous.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.